Comparing Adaptimmune Therapeutics (NASDAQ:ADAP) & Genenta Science (NASDAQ:GNTA)

Genenta Science (NASDAQ:GNTA) and Adaptimmune Therapeutics (NASDAQ:ADAP) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, dividends, risk, profitability, analyst recommendations and institutional ownership.

Valuation and Earnings

This table compares Genenta Science and Adaptimmune Therapeutics”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genenta Science	N/A	N/A	-$9.64 million	N/A	N/A
Adaptimmune Therapeutics	$178.03 million	0.09	-$70.81 million	($0.65)	-0.09

Genenta Science has higher earnings, but lower revenue than Adaptimmune Therapeutics.

Profitability

This table compares Genenta Science and Adaptimmune Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Genenta Science	N/A	N/A	N/A
Adaptimmune Therapeutics	-260.82%	-163.73%	-75.83%

Volatility & Risk

Genenta Science has a beta of 0.55, meaning that its stock price is 45% less volatile than the S&P 500. Comparatively, Adaptimmune Therapeutics has a beta of 2.49, meaning that its stock price is 149% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings and price targets for Genenta Science and Adaptimmune Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genenta Science	1	0	0	0	1.00
Adaptimmune Therapeutics	2	5	1	0	1.88

Adaptimmune Therapeutics has a consensus target price of $1.35, indicating a potential upside of 2,234.48%. Given Adaptimmune Therapeutics’ stronger consensus rating and higher probable upside, analysts plainly believe Adaptimmune Therapeutics is more favorable than Genenta Science.

Institutional and Insider Ownership

15.1% of Genenta Science shares are held by institutional investors. Comparatively, 31.4% of Adaptimmune Therapeutics shares are held by institutional investors. 29.0% of Genenta Science shares are held by company insiders. Comparatively, 12.4% of Adaptimmune Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Adaptimmune Therapeutics beats Genenta Science on 6 of the 11 factors compared between the two stocks.

About Genenta Science

Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Its lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. The company is developing Temferon for use in the treatment of other solid tumor indications, locally advanced hepatocellular carcinoma, and intra-hepatic cholangiocarcinoma. In addition, it develops biologic platform to deliver immunomodulatory molecules directly to the tumor by infiltrating monocytes/macrophages. Genenta Science S.p.A. was incorporated in 2014 and is headquartered in Milan, Italy.

About Adaptimmune Therapeutics

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers. The company has strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic and allogeneic T-cell therapies; research, collaboration, and license agreement with Universal Cells, Inc.; third-party collaborations with Noile-Immune and Alpine Immune Sciences; and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.